Neogenomics (NEO) Income from Continuing Operations (2010 - 2026)

Neogenomics has reported Income from Continuing Operations for 17 years, with the latest figure at 17106000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 34.01% year-over-year to 17106000.0; the trailing twelve-month figure through Mar 2026 stood at 99208000.0 (down 27.87% YoY), and the FY2025 full-year result was 108025000.0, down 37.22% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 17106000.0, down from 9881000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 9881000.0 in Q4 2025, with the low at 49408000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 25651470.59 across 5 years, with a median of 24331000.0 in 2023.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 146.53% — and 2023, when it soared 49.76%.
• Neogenomics' Income from Continuing Operations stood at 22687000.0 in 2022, then jumped by 36.85% to 14326000.0 in 2023, then decreased by 6.97% to 15324000.0 in 2024, then soared by 35.52% to 9881000.0 in 2025, then sank by 73.12% to 17106000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 17106000.0 (Q1 2026), 9881000.0 (Q4 2025), and 27129000.0 (Q3 2025), per Business Quant data.